Glucocorticoid receptor antagonists - Pipeline Insight, 2024

Glucocorticoid receptor antagonists - Pipeline Insight, 2024

DelveInsight’s, “Glucocorticoid Receptor Antagonist - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Glucocorticoid Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glucocorticoid Receptor Antagonist Understanding

Glucocorticoid Receptor Antagonist: Overview

Glucocorticoids (GCs) are adrenal hormones involved in the stress response, regulating processes such as immune function and metabolism. Glucocorticoids mediate numerous essential processes in the human body via binding to the glucocorticoid receptor (GR). Excessive GR signaling can cause disease, and GR antagonists can be used to treat many symptoms of glucocorticoid-induced pathology.

Function – Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus.

Glucocorticoid Receptor Antagonist- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Glucocorticoid Receptor Antagonist which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders.

Glucocorticoid Receptor Antagonist Emerging Drugs Chapters

This segment of the Glucocorticoid Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glucocorticoid Receptor Antagonist Emerging Drugs

• Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including Cushing’s syndrome and adrenal, ovarian and pancreatic cancer. The drug is being evaluated currently in Phase III stage of development for Cushing syndrome and pancreatic cancer. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing’s syndrome and pancreatic cancer.

• Miricorilant: Corcept Therapeutics

Miricorilant (CORT 118335), dual selective glucocorticoid receptor modulator and mineralocorticoid receptor antagonist is being developed by Corcept Therapeutics, for the treatment of antipsychotic-induced weight gain. The Phase II clinical trials are underway to assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Further product details are provided in the report……..

Glucocorticoid Receptor Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Glucocorticoid Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Glucocorticoid Receptor Antagonist

There are approx. 10+ key companies which are developing the Glucocorticoid Receptor Antagonist. The companies which have their Glucocorticoid Receptor Antagonist drug candidates in the most advanced stage, i.e. Phase III include Corcept Therapeutics.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glucocorticoid Receptor Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glucocorticoid Receptor Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucocorticoid Receptor Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucocorticoid Receptor Antagonist drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glucocorticoid Receptor Antagonist R&D.
• The therapies under development are focused on novel approaches for Glucocorticoid Receptor Antagonist.

Glucocorticoid Receptor Antagonist Report Insights

• Glucocorticoid Receptor Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glucocorticoid Receptor Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Glucocorticoid Receptor Antagonist drugs?
• How many Glucocorticoid Receptor Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Glucocorticoid Receptor Antagonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucocorticoid Receptor Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glucocorticoid Receptor Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?